Antisense strategies and therapeutic applications

American Journal of Health-System Pharmacy

Volumn 53, Issue 2, 1996, Pages 151-160

  Putnam, David A ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Allergies; Arthritis; Gene therapy; Genetic engineering; Hepatitis B infections; HIV infections; Neoplasms; Oligonucleotides; Papillomavirus infections; Restenosis

Indexed keywords

ANTIGENE SEQUENCE; ANTISENSE OLIGONUCLEOTIDE; DOUBLE STRANDED DNA; DRUG CARRIER; LIPOSOME; MESSENGER RNA; NANOPARTICLE; NUCLEASE; POLYMER; RIBOZYME; UNCLASSIFIED DRUG;

ALLERGY; ARTICLE; CANCER CHEMOTHERAPY; DRUG MECHANISM; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RESTENOSIS; RHEUMATOID ARTHRITIS; RNA PROCESSING; RNA TRANSLATION; VIRUS INFECTION;

EID: 0030035031     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.2.151     Document Type: Article

References (76)

1. Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem Rev. 1990; 90:543-4.
2. Liebhaber SA, Cash FE, Shakin SH. Translationally associated helix-destabilizing activity in rabbit reticulocyte lysate. J Biol Chem. 1984; 259:15597-602.
3. Walder RY, Walder JA Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A. 1988; 85:5011-5.
4. Hanvey JC, Shimizu M, Wells RD. Site-specific inhibition of EcoRI restriction/modification enzymes by a DNA triple helix. Nucleic Acids Res. 1990; 18:157-61.
5. Helene C. The anti-gene strategy: control of gene expression by triplex-forming oligonucleotides. Anticancer Drug Des. 1991; 6:569-74.
6. Cohen JS. Oligonucleotides as therapeutic agents. Pharmacol Ther. 1991; 52:221-5.
7. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature. 1987; 328:596-610
8. Rossi JJ, Elkins D, Zaia JA et al. Ribozymes as anti-HIV therapeutic agents: principles, applications, and problems. AIDS Res Hum Retroviruses. 1992; 8:183-9.
9. Goodchild J, Kohli V. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch Biochem Biophys. 1991; 284:386-91.
10. Saxena SK, Ackerman EJ. Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. J Biol Chem. 1990; 265:17106-9.
11. Taylor N, Rossi JJ. Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of non-targeted sequences and secondary structure on ribozyme cleavage activity. Antisense Res Dev. 1991; 1:173-86.
12. Zamecnik PC, Goodchild Y, Taguchi Y et al. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A. 1986; 83:4143-6.
13. Agrawal S, Goodchild J, Civeira MP et al. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988; 85:7079-83.
14. Sarin PS, Agrawal S, Civeira MP et al. Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci U S A. 1998; 85:7448-51.
15. Matsukura M, Shinozuka K, Zon G et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987; 84:7706-10.
16. Zon G. Innovations in the use of antisense oligonucleotides. Ann N Y Acad Sci. 1990; 616:161-72.
17. Matsukura M, Zon G, Shinozuka K et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev(art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989; 86:4244-8.
18. Chang P, Cantin EM, Zaia JA et al. Ribozyme-mediated sitespecific cleavage of the HIV-1 genome. Clin Biotechnol. 1990; 2:23-31.
19. Hampel A, Tritz R, Hicks M et al. Hairpin catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res. 1990; 18:299-304.
20. Perillo RP, Schiff ER, Davie GL et al. A randomized, controlled trial of Interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990; 323:295-301.
21. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985; 317:489-95.
22. Offensperger WB, Offensperger S, Walter E et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 1993; 12:1257-62.
23. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem. 1992; 267:12436-9.
24. Kulka M, Smith CC, Aurelian L et al. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc Natl Acad Sci U S A. 1989; 86:6868-72.
25. Pagano JS, Jimenez G, Sung NS et al. Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann N Y Acad Sci. 1992; 660:107-16.
26. Cowsert LM, Fox MC, Zon G et al. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993; 37:171-7.
27. Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol. 1993; 9:L1-12.
28. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer. 1993; 67:869-76.
29. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res. 1991; 51:4505-10.
30. Tidd DM. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res. 1990; 10:1169-82.
31. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyocytic cells and induces differentiation. Mol Cell Biol. 1988; 8:963-73.
32. Kimura S, Maekawa T, Hirakawa K et al. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 1995; 55:1379-84.
33. McManaway ME, Neckers LM, Loke SL et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet. 1990; 335:808-11.
34. Rosolen A, Whitesell L, Ikegaki N et al. Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line. Cancer Res. 1990; 50:6316-22.
35. Whitesell L, Rosolen A, Neckers LM. Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol Cell Biol. 1991; 11:1360-1.
36. Anfossi G, Gerwirtz AM, Calabretta B. Anoligomer complementary to c-myb encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A. 1989; 86:3379-83.
37. Calabretta B, Sims RB, Valtieri M et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study with relevance to bone marrow purging. Proc Natl Acad Sci U S A. 1991; 88:2351-5.
38. Gewirtz AM. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant. 1994; 14(Suppl 3):S57-61.
39. Luger SM, Ratajczak MZ, Stadtmauer EA et al. Autografting for chronic myelogenous leukemia (Cml) with c-myb antisense oligodeoxynucleotide purged bone marrow: a preliminary report Blood. 1994; 84:(Suppl 1):151. Abstract.
40. Epstein ST, Speir E, Unger EF et al. The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol. 1994; 23:1278-88.
41. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisted: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992; 20:1284-93.
42. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the mRNA encoding PCNA. Circulation. 1992; 86:538-47.
43. Pickering G, Weir L, Jekanowski J et al. Inhibition of proliferation of human vascular smooth muscle cells using antisense oligonucleotides to PCNA. J Am Coll Cardiol. 1992; 19:165. Abstract.
44. Biro S, Fu YM, Yu ZX et al. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993; 90:654-8.
45. Shi Y, Hutchinson HG, Hall DJ et al. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 1993; 88:1190-5.
46. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992; 70:835-43.
47. Bennett MR, Anglin S, McEwan JR et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 1994; 93:820-8.
48. Morishita R, Gibbons GH, Ellison KE et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994; 93:1458-64.
49. Nietfeld JJ, Wilbrink B, Helle M et al. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum. 1990; 33:1695-701.
50. Nietfeld JJ, Duits AJ, Tilanus MGJ et al. Antisense oligonucleotides, a novel tool for the control of cytokine effects on human cartilage. Arthritis Rheum. 1994; 37:1357-62.
51. Hall TJ, Brostoff J. Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer. Immunology. 1992; 77:462-4.
52. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods. 1986; 13:97-102.
53. Akhtar S, Kole R, Juliano RL. Stability of modified antisense oligodeoxynucleotides in cellular extracts and sera. Life Sci. 1991; 49:1793-801.
54. Stein CA, Tonkinson JL, Yakobov L. Phosphorothioate oligodeoxynucleotides: antisense inhibitors of gene expression? Pharmacol Ther. 1991; 52:365-74.
55. Ede NJ, Tregear GW, Haralambidis J. Routine preparation of thiol oligonucleotides: application to the synthesis of oligonucleotide-peptide hybrids. Bioconjug Chem. 1994; 5:373-8.
56. Iversen PL, Shu S, Meyer A et al. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 1992; 2:211-2.
57. Geiser T. Large-scale economic synthesis of antisense phosphorothioate analogues of DNA for preclinical investigations. Ann N Y Acad Sci. 1990; 616:173-83.
58. Rossi JJ, Cantin EM, Sarver N et al. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacol Ther. 1991; 50:245-54.
59. Baum R. Chemists create new oligonucleotide analogs for 'antisense' applications. Chem Eng News. 1994; Apr 18:21-2. News.
60. Wagner RW, Matteucci MD, Lewis JG et al. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 1993; 260:1510-3.
61. Loke SL, Stein CA, Zhang XH et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989; 86:3474-8.
62. Jaroszewski JW, Cohen JS. Cellular uptake of antisense oligonucleotides. Adv Drug Delivery Rev. 1991; 6:235-40.
63. Klibanov AL, Maruyama K, Torchilin VP et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268:235-7.
64. Allen TM, Hansen C, Martin F et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991; 1066:29-36.
65. Gentry C. The development of a model system to study the specific binding activity of long-circulating immunoliposomes. Salt Lake City, UT: University of Utah; 1994. Dissertation.
66. Tari AM, Tucker SD, Deisseroth A et al. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood. 1994; 84:601-7.
67. Kariko K, Megyen K, Xiao Qi et al. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. 1994; 352:41-4.
68. Clarenc JP, Degols G, Leonetti JP et al. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des. 1993; 8:81-4.
69. Ryser HJP, Shen W-C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci U S A. 1978; 75:3867-70.
70. Leonetti JP, Degols G, Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug Chem. 1990; 1:149-53.
71. Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv Polym Sci. 1995; 122:55-123.
72. Kopecek J. The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J Controlled Release. 1990; 11:279-90.
73. Schwab G, Chavany C, Duroux I et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci U S A. 1994; 91:10460-4.
74. Agrawal S, Temsamani J, Galbraith W et al. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995; 28:7-16.
75. Chem TL, Miller P, Ts'O P et al. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection in mice. Drug Metab Dispos Biol Fate Chem. 1990; 18:815-8.
76. Bayever E, Iversen PL, Bishop MR et al. Systemic adminstration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res Dev. 1993; 3:383-90.